Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

35.82 -1.06 (-2.87%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab ↗

June 11, 2025

Via Benzinga

10 Analysts Assess Beam Therapeutics: What You Need To Know ↗

May 07, 2025

Via Benzinga

Why Beam Therapeutics Stock Tanked on Tuesday ↗

May 06, 2025

Via The Motley Fool

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Analyst Expectations For Beam Therapeutics's Future ↗

February 27, 2025

Via Benzinga

(BEAM) - Analyzing Beam Therapeutics's Short Interest ↗

January 31, 2025

Via Benzinga

Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews ↗

January 29, 2025

Via Benzinga

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views ↗

November 06, 2024

Via Benzinga

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease ↗

April 07, 2025

Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗

April 04, 2025

Via Benzinga

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' ↗

April 04, 2025

Via Benzinga

Beam Therapeutics's Earnings: A Preview ↗

November 04, 2024

Via Benzinga

Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗

September 11, 2024

Via Benzinga

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

March 28, 2025

Via Benzinga

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock ↗

March 28, 2025

Via Benzinga

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen ↗

March 22, 2025

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Via Benzinga

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity ↗

March 10, 2025

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Via Benzinga

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% ↗

March 04, 2025

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies ↗

February 22, 2025

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday ↗

February 15, 2025

Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.

Via Benzinga

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday ↗

February 14, 2025

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains ↗

December 09, 2024

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.

Via Benzinga

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

November 06, 2024

Via Benzinga

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial ↗

November 05, 2024

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency

Via Benzinga

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.